secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kezar Life Sciences, Inc. (KZR)
CIK:        0001645666
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001645666-25-000026
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KZR Q1 2025 net loss $16.6M; positive PORTOLA data in AIH
---------------------------------------------------------

- Cash $114.4M at March 31, 2025, down from $132.2M at Dec 31, 2024.
- Net loss $16.6M ($2.27/share) vs $21.7M ($2.98) in Q1 2024.
- PORTOLA Phase 2a: 36% zetomipzomib patients achieved CR with steroid taper vs 0% placebo in relapsed AIH.
- R&D expenses fell $5.0M to $12.2M due to PALIZADE trial termination.
- Responding to FDA partial clinical hold on PORTOLA; no flares in CR patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/0001645666-25-000026-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645666/000164566625000026/kzr-20250513.htm
  HTML page:      https://secwatch.observer/filing/0001645666-25-000026

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer